☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
frequency
Novartis' Adakveo (crizanlizumab) Receives the US FDA's Approval for Reducing the Frequency of VOCs in Sickle Cell Disease
November 18, 2019
Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine
May 7, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.